Pasireotide
- Generic Name
- Pasireotide
- Brand Names
- Signifor
- Drug Type
- Small Molecule
- Chemical Formula
- C58H66N10O9
- CAS Number
- 396091-73-9
- Unique Ingredient Identifier
- 98H1T17066
- Background
Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
- Indication
For the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option.
- Associated Conditions
- Acromegaly, Cushing's Disease
- Associated Therapies
- -
An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT00171730
- Locations
- 🇺🇸
NYU / VA Medical Center, New York, New York, United States
🇨🇭Novartis Investigative Site, Lausanne, Switzerland
🇺🇸Cedars Sinai Medical Center Dept. of Pituitary Ctr., Los Angeles, California, United States
Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT00171951
- Locations
- 🇬🇧
Novartis Investigative Site, Belfast, United Kingdom
🇺🇸Oregon Health & Sciences University Dept.ofOregonHealth&SciencesU., Portland, Oregon, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.